EW - Edwards Lifesciences Corp Stock Analysis
Edwards Lifesciences Corp (EW) is a publicly traded company listed on the NYSE. It operates in the Medical Devices industry, part of the broader Healthcare sector. The company has a market capitalization of 46.04B, generates annual revenue of 6.07B, and reports net income of 1.09B. As of the latest data, the stock is trading at 79.33 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is trading at a high valuation compared to the market average, suggesting investor optimism or growth expectations. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.
Analyst recommendation stands at Hold (3.98), indicating current market sentiment. Institutional ownership is reported at 87.63%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 11.87%, trading within a 52-week range of 65.94 - 87.89.
EW - Edwards Lifesciences Corp
79.33
Analyst Consensus
Hold 3.98
EW – Analyst Rating Summary
- Strong Buy: 11
- Buy: 20
- Hold: 12
- Sell: 0
- Strong Sell: 0
- Total Analysts: 43
| Index: | S&P 500 | P/E: | 42.82 | EPS (ttm): | 1.85 | Insider Own: | 1.37% | Shs Outstand: | 580.30M | Perf Week: | -0.55% |
| Market Cap: | 46.04B | Forward P/E: | 23.94 | EPS next Y: | 3.31 | Insider Trans: | -1.24% | Shs Float: | 572.37M | Perf Month: | -4.43% |
| Income(ttm): | 1.09B | PEG: | 1.79 | EPS next Q: | 0.73 | Inst Own: | 87.63% | Short Float: | 1.41% | Perf Quarter: | -5.65% |
| Revenue(ttm): | 6.07B | P/S: | 7.59 | EPS this Y: | 15.77% | Inst Trans: | -1.62% | Short Ratio: | 2.23 | Perf Half Y: | 3.12% |
| Book/sh: | 17.57 | P/B: | 4.51 | EPS next Y: | 11.82% | ROA: | 10.23% | Short Interest: | 8.09M | Perf Year: | 11.87% |
| Cash/sh: | 5.17 | P/C: | 15.35 | EPS next 5Y: | 13.35% | ROE: | 13.59% | 52W Range: | 65.94 - 87.89 | Perf YTD: | -6.94% |
| Dividend Est.: | - | P/FCF: | 57.24 | EPS past 3/5Y: | -9.12% 7.03% | ROIC: | 9.99% | 52W High: | 87.89 -9.74% | Beta: | 0.94 |
| Dividend TTM: | - | Quick Ratio: | 3.29 | Sales past 3/5Y: | 4.08% 6.70% | Gross Margin: | 79.71% | 52W Low: | 65.94 20.31% | Perf 5Y: | -9.92% |
| Dividend Ex-Date: | - | Current Ratio: | 4.00 | EPS Y/Y TTM: | 26.82% | Oper. Margin: | 26.75% | RSI (14): | 41.37 | Volatility: | 3.58% 2.58% |
| Employees: | 15800 | Debt/Eq: | 0.06 | Sales Y/Y TTM: | 6.00% | Profit Margin: | 17.92% | Recom: | 1.81 | Target Price: | 97.25 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.06 | EPS Q/Q: | -75.99% | Payout: | 0.00% | Rel Volume: | 3.11 | Prev Close: | 77.05 |
| Sales Surprise: | 1.47% | EPS Surprise: | -6.13% | Sales Q/Q: | 13.26% | Earnings: | Feb 10 AMC | Avg Volume: | 3.63M | Price: | 79.33 |
| SMA20: | -3.00% | SMA50: | -5.23% | SMA200: | -0.30% | Undervalued: 22.59% | Volume: | 11,282,426 | Change: | 2.96% | |
Graham Classic formula value: 58.48
(P/E=8 * 1g) Min value: 35.47
(current P/E * 2g) Max value: 115.49
Average value: 69.81
About Edwards Lifesciences Corp
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the following geographical segments: United States, Europe, Japan, and Rest of World. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.